WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here

Search

Track Your Article

Abstract

ICSI OUTCOME AFTER USE OF DURIAN FOR INFERTILE MALE

*Liqaa Rahi Jassim, Sallama Hamid Abbas and Sabah Mahdi Hussein

ABSTRACT

Background: In vitro fertilization (IVF) cycle outcome correlates with the severity of seminal fluid analysis abnormalities as well as maternal age, number of follicles picked up and endometrial condition at time of embryo transfer. At our center male infertility comprise about 65% of total infertility cases which we saw during the last 3 years. Objective: To evaluate intracytoplasmic sperm injection (ICSI) outcome in term of fertilization and pregnancy rates with and without the use of durion sachets for the male of the infertile couples (including male with azoospermia). Methods: Prospective study was carried out during the period between November 2009 and November 2012, 302 couples were admitted for icsi cycle due to abnormal SFA and abnormal hormonal profile, 165 patients were treated by empirical treatment which consists of vitamin E, L-carnitine and Zinc, and those were compared with 110 patients who were further supplemented with Durion sachets. Patients with abnormal SFA were divided into three groups. Group A: 27 patients who received no treatment. Group B: 165 patients were received the empirical treatment. (L-carnitine), vitamin E and Zinc. Group C: 110 patients were received the empirical treatment and durion. ICSI was performed in 302 consecutive IVF cycles on couples with a defined severe male infertility or with a proven failure of fertilization, neither male nor female partners were chosen from a waiting list or any other selective basis, including age, prior or anticipated ovarian response, or oocyte number and quality, there were no age limit and cancellation rate was minimal about 10% of all cases underwent this study. Introduction of durion in our center was started to be used in 2 groups 1st group patients' severe oligoasthenoteratospermia OAT 2nd group patients with mild to moderate abnormality in seminal analysis and have previous history of failed ivf cycle due to failed fertilization with an oocyte in Metaphase II stage.

Keywords: Durion, ICSI, male factor infertility, ICSI outcome.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More